Vancouver-based biotechnology company CytoDyn announced Friday that it has now enrolled seven patients in a test to see if the company’s flagship treatment product can be used to effectively treat COVID-19.
The treatment is an antibody called leronlimab, originally created to treat HIV, but CytoDyn theorized that it could also function as an anti-inflammatory agent that could prevent COVID-19 patients from developing Acute Respiratory Distress Syndrome, a potentially lethal complication of COVID-19.
CytoDyn received permission from the Food and Drug Administration to fast-track a test, and it announced Friday that it has begun to receive results from the first four patients, all of whom are at a medical facility in New York.
The company also announced on Friday that it submitted another refinement to its proposal to the FDA for a broader clinical trial that would test 75 patients for up to six weeks.
